VA could save $1.6B by balancing patient-provider ratio

According to a new study from Lightning Bolt, providers of automated physician scheduling, the Department of Veterans Affairs (VA) could save $1.6 billion annually if the organization could balance patient and physician volumes.

The study compared patient and physician volumes from Kaiser Permanente and the VA to evaluate the ratio between the two organizations. At Kaiser Permanente, there were 554 patients per physician, a 55 percent higher ratio then the 356 patients per physician at the VA.

While the two organizations are similar in size, the VA sees a significantly fewer patients a day. If the VA were able to balance the patient-provider ratio, the study estimates the VA health system could save $1.6 billion annually. The savings could then be used to increase the VA physician’s salaries to reach the national average, bringing in more talent and reducing turnovers, while still saving over $400 million a year.

“To catch up to Kaiser Permanente, the VA can start by using AI technology to optimize physician work schedules,” said Suvas Vajracharya, PhD, CEO of Lightning Bolt Solutions. “Patient access technology now allows health systems to match the right patient, to the right provider, at the right time—more efficiently using physician clinical expertise and reducing patient wait times.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.